Advancing new therapies for multiple cancers with PAM (PI3K/AKT/mTOR) pathway involvement

Celcuity is a clinical-stage biotechnology company focused on developing a better way to address cellular abnormalities that drive tumor growth. Our teams of drug development scientists, biochemists, and molecular biologists are working to advance new targeted therapies for cancers involving the PAM (PI3K/AKT/mTOR) pathway. This pathway plays a critical role as biological driver of a range of tumor types, including breast, prostate, lung, endometrial, colon, and ovary.

Our lead product candidate, gedatolisib, is a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, and/or mTORC1 alone or together. Gedatolisib thus offers hope to meaningfully extend the time that a patient’s tumors are not progressing.